Clinical manifestations and treatment outcomes in prurigo pigmentosa (Nagashima disease): A systematic review of the literature.
AOSD, adult-onset Still disease
CARP, confluent and reticulated papillomatosis
IL-6, interleukin 6
Nagashima
Nagashima's disease
PP, prurigo pigmentosa
inflammatory skin disease
ketogenic diet
ketosis
prurigo pigmentosa
systematic review
Journal
JAAD international
ISSN: 2666-3287
Titre abrégé: JAAD Int
Pays: United States
ID NLM: 101774762
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
accepted:
10
03
2021
entrez:
19
8
2021
pubmed:
20
8
2021
medline:
20
8
2021
Statut:
epublish
Résumé
Prurigo pigmentosa (PP) is a rare inflammatory dermatosis characterized by pruritic erythematous papules that coalesce to form a reticulate pattern. PP is often misdiagnosed, and patients are treated with ineffective therapies. Although the majority of reports about PP are from East Asia, patients of all backgrounds can be affected. To perform a systematic review of reported PP cases with the purpose of summarizing the clinical presentation and treatment of PP. MEDLINE and Embase were searched for original articles describing PP. We identified 115 studies from 24 countries representing 369 patients to include in the analysis. Of the 369 patients included in the analysis, the mean age was 25.6 years (range: 13-72 years) with 72.1% (266 of 369) female. Risk factors or aggravating factors were described in 52.3% (193 of 369) of patients and included dietary changes (25.5%, 94 of 369), friction (8.4%, 31 of 369), sweat (7.6%, 28 of 369), and ketonuria (5.1%, 19 of 369). Of those patients who experienced PP following dietary changes, 40.4% (38 of 94) started a ketogenic diet. Minocycline monotherapy was the most frequently prescribed treatment for PP (20.9%, 77 of 369), achieving complete resolution in 48.1% (37 of 77) of patients. PP is sometimes associated with ketogenic diets and can be effectively managed with oral tetracyclines.
Sections du résumé
BACKGROUND
BACKGROUND
Prurigo pigmentosa (PP) is a rare inflammatory dermatosis characterized by pruritic erythematous papules that coalesce to form a reticulate pattern. PP is often misdiagnosed, and patients are treated with ineffective therapies. Although the majority of reports about PP are from East Asia, patients of all backgrounds can be affected.
OBJECTIVES
OBJECTIVE
To perform a systematic review of reported PP cases with the purpose of summarizing the clinical presentation and treatment of PP.
METHODS
METHODS
MEDLINE and Embase were searched for original articles describing PP. We identified 115 studies from 24 countries representing 369 patients to include in the analysis.
RESULTS
RESULTS
Of the 369 patients included in the analysis, the mean age was 25.6 years (range: 13-72 years) with 72.1% (266 of 369) female. Risk factors or aggravating factors were described in 52.3% (193 of 369) of patients and included dietary changes (25.5%, 94 of 369), friction (8.4%, 31 of 369), sweat (7.6%, 28 of 369), and ketonuria (5.1%, 19 of 369). Of those patients who experienced PP following dietary changes, 40.4% (38 of 94) started a ketogenic diet. Minocycline monotherapy was the most frequently prescribed treatment for PP (20.9%, 77 of 369), achieving complete resolution in 48.1% (37 of 77) of patients.
CONCLUSIONS
CONCLUSIONS
PP is sometimes associated with ketogenic diets and can be effectively managed with oral tetracyclines.
Identifiants
pubmed: 34409375
doi: 10.1016/j.jdin.2021.03.003
pii: S2666-3287(21)00017-1
pmc: PMC8362297
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
79-87Informations de copyright
© 2021 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Dr Jensen Yeung has been a speaker, consultant, and investigator for AbbVie, Allergan, Amgen, Astellas, Boehringer Ingelheim, Celgene, Centocor, Coherus, Dermira, Eli Lilly, Forward, Galderma, GSK, Janssen, Leo, Medimmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Takeda, UCB, Valeant, and Xenon. Dr Mufti, Dr Mirali, author Abduelmula, Dr McDonald, Dr Alabdulrazzaq, and author Sachdeva have no conflicts of interest to declare.
Références
JAMA Dermatol. 2017 Mar 1;153(3):353-354
pubmed: 28099972
Clin Rheumatol. 2014 Jan;33(1):49-55
pubmed: 24005839
J Fam Pract. 2019 Mar;68(2):113; 114; 116
pubmed: 30870537
J Am Acad Dermatol. 1996 Mar;34(3):509-11
pubmed: 8609269
Am J Clin Dermatol. 2015 Dec;16(6):533-43
pubmed: 26334426
J Dermatol. 2006 Jan;33(1):55-8
pubmed: 16469087
J Am Acad Dermatol. 2018 Nov;79(5):947-949
pubmed: 30245097
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
Malays Fam Physician. 2019 Apr 30;14(1):42-46
pubmed: 31289632
J Dermatol. 1981 Apr;8(2):125-32
pubmed: 7021624
Ann Dermatol Venereol. 2019 Mar;146(3):215-218
pubmed: 30104019
Case Rep Dermatol Med. 2018 Jul 9;2018:9406797
pubmed: 30105102
J Dermatol. 2016 Jul;43(7):846-7
pubmed: 26872306
Acta Derm Venereol. 2002;82(4):302-3
pubmed: 12361140
Diabetes Metab Res Rev. 1999 Nov-Dec;15(6):412-26
pubmed: 10634967
Chang Gung Med J. 2010 Mar-Apr;33(2):157-63
pubmed: 20438668
Cutis. 2019 Mar;103(3):E10-E13
pubmed: 31039240
Hawaii J Med Public Health. 2018 May;77(5):114-117
pubmed: 29761029
JAAD Case Rep. 2017 Dec 19;4(1):77-80
pubmed: 29387756
Int J Dermatol. 2011 Jan;50(1):36-43
pubmed: 21182500
J Cutan Pathol. 2017 Jan;44(1):20-27
pubmed: 27686778
Am J Dermatopathol. 2017 Apr;39(4):267-274
pubmed: 27533074
Indian J Dermatol Venereol Leprol. 2006 Nov-Dec;72(6):405-9
pubmed: 17179613
Arch Dermatol. 1993 Mar;129(3):367, 370
pubmed: 8447681
Br J Pharmacol. 2013 May;169(2):337-52
pubmed: 23441623
JAMA Dermatol. 2019 Mar 1;155(3):377-378
pubmed: 30649131
Acta Derm Venereol. 2014 Jan;94(1):102-3
pubmed: 23624720
Int J Gynaecol Obstet. 2007 Sep;98(3):261-2
pubmed: 17532321
J Invest Dermatol. 1992 Feb;98(2):135-40
pubmed: 1732379
J Cutan Pathol. 2016 Oct;43(10):809-14
pubmed: 27652586
Clin Exp Dermatol. 2009 Dec;34(8):e584-6
pubmed: 19489866
J Dermatol. 2015 Apr;42(4):436-7
pubmed: 25728465
Pediatr Dermatol. 2014 Jul-Aug;31(4):523-5
pubmed: 24846714
J Eur Acad Dermatol Venereol. 2021 Jun 24;:
pubmed: 34166545